Roche ends heart drug trial

  • Swiss drugmaker Roche has called an end to efforts to develop a heart disease drug on the back of poor data results.

    The Data and Safety Monitoring Board recommended halting the trial due to a lack of meaningful worth of the drug, dalcetrapib.

    Industry analysts claimed the drug could have achieved $10 billion in annual sales.